Eris Lifesciences FY25 results: revenue rises 44% YoY

Why Eris Lifesciences’ FY25 print matters

Eris Lifesciences has positioned itself as a fast-growing, super-speciality focused Indian pharmaceutical company, with a portfolio built around branded generics. The company’s FY25 results are being watched closely because they follow a major step-up in scale after an acquisition and continued focus on chronic therapies. India’s broader pharmaceutical market is also in a growth phase, making market-share gains and portfolio depth important for medium-term execution.

Company snapshot and therapy focus

Eris Lifesciences is engaged in manufacturing, marketing, and selling branded generics across India. Its key therapy areas include Cardiology, Diabetology, Endocrinology, Gastroenterology, ENT, Orthopedics, Pediatrics, and Gynecology. The company is described as a leading player in domestic branded formulations, and it has been cited as ranking among the top 20-25 companies in the Indian Pharmaceutical Market (IPM).

FY25 results: revenue, EBITDA and PAT

For FY25, Eris Lifesciences reported revenue of ₹2,894 crore, a 44% year-on-year increase. Full-year EBITDA was ₹1,017 crore with a 35% EBITDA margin. Profit after tax (PAT) for FY25 was ₹375 crore, with a 13% PAT margin.

The company also disclosed cash conversion metrics: operating cash flows were 105% of EBITDA in FY25. These figures were presented as part of the company’s FY25 earnings communication.

Q4FY25 performance: growth and margins

In Q4FY25, Eris reported revenue of ₹705 crore, up 28% year-on-year. Q4 EBITDA came in at ₹252 crore, translating to an EBITDA margin of 36%. Q4 PAT was reported at ₹102 crore, with a 14% PAT margin.

Separately, another data point in the provided information cites Q4FY25 revenue of ₹705.30 crore and net profit of ₹93.84 crore, with a net profit margin of 13.16%. The same dataset also mentions Q4FY25 revenue of ₹713.31 crore and net profit of ₹93.84 crore. These figures indicate that different sources may be using different consolidation scopes or reporting line items, but all point to strong year-on-year growth in the March quarter.

Management commentary and business highlights

Chairman and Managing Director Amit Bakshi said the Branded Formulations business delivered 10% organic growth in Q4. For FY25, the company highlighted that its Organic Domestic Branded Formulations business grew 9% year-on-year.

The company also reported that the Domestic Branded Formulations segment revenue grew 32% year-on-year, and the segment’s EBITDA margin improved by 207 basis points. Another business metric disclosed was brand strength: 15 out of the top-25 mother brands rank among the top-5 in their respective markets, and five mother brands have revenues above ₹100 crore.

The Biocon Biologics acquisition and injectables push

Eris Lifesciences acquired Biocon Biologics’ Indian branded formulations business in March 2024 for ₹1,242 crore. The deal was described as strengthening Eris’ presence in the ₹30,000 crore Indian injectables market, and improving its position in the insulin segment.

The acquisition is projected to elevate Eris’ diabetes care unit to an annual revenue of ₹1,000 crore, potentially making it the fifth largest diabetes portfolio in India (as per the provided projection). Eris’ oral diabetic market share was also cited as improving to 5.6%.

Balance sheet and competitive landscape

Eris’ total assets were reported at ₹6,741.90 crore as of March 2024, reflecting a larger operating base after investments and expansion. The company also operates in a competitive environment alongside large domestic peers. Competitors explicitly cited include Sun Pharma, Cipla, and Dr. Reddy’s Laboratories.

Industry context: India pharma growth backdrop

The Indian pharmaceutical sector was described as booming, with projections to reach ₹238,000 crore by 2025. A separate projection cited was an estimated USD 174.31 billion by 2033, with an 11.32% CAGR from 2025-2033. For companies like Eris that focus on chronic therapy segments and branded prescriptions, this backdrop supports volume growth and category expansion, but also keeps the competitive intensity high.

Key numbers at a glance

Market impact and what investors typically track next

The FY25 print highlights two drivers visible in the disclosed numbers: strong top-line growth and stable-to-improving operating margins. The acquisition-led scale-up in diabetes and injectables matters because it changes Eris’ revenue mix and can influence working capital and integration costs, even when consolidated growth is strong.

For listed-market context, the provided snapshot also mentions market cap of ₹18,595.36 crore, a current price around ₹1,342, and ROE of 12.9%. After a year with 44% revenue growth, investors typically track whether branded formulation growth stays resilient, whether the diabetes portfolio achieves the projected scale, and whether cash conversion remains above EBITDA.

Conclusion

Eris Lifesciences’ FY25 results show revenue of ₹2,894 crore and PAT of ₹375 crore, with Q4 margins holding up alongside rapid year-on-year growth. The March 2024 Biocon Biologics acquisition remains central to the company’s diabetes and injectables expansion narrative. The next key checkpoints will be continued disclosure on portfolio performance, integration progress, and sustained cash flow conversion in subsequent quarters.